Mobile website
Expert Forum
Progresses of research on CD19-CAR-T cell therapy for refractory/relapsed acute lymphocytic leukemia
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Patients with refractory/relapsed acute lymphoblastic leukemia (ALL) have poor prognosis and short survival time, which has become an international conundrum. Chimeric antigen receptor gene-modified T cell (CAR-T) therapy has been the most promising application targeted immunotherapy so far. CD19-targeted CAR-T (CD19-CAR-T) therapy could reach more than 90% of complete remission rate (CR) for the children and adults with refractory/relapsed ALL, of which efficacy was much higher than that of chemotherapy. However, complications, such as cytokine release syndrome (CRS), serious neurotoxicity (SNT), off-target effect and relapse, seriously impeded its further clinical application. This article mainly reviewed the latest progresses of researches on the manufacture technologies, the conditioning regimens, the cell infusion doses and the prevention and treatment strategies of complications for the CAR-T therapy.
Keywords:
Project Supported:
Project supported by the National Key Basic Research Development Program (973 Program) (No. 2015CB964900)
Clc Number:
